Shanghai Rightongene Biotechnology Third Quarter 2024 Earnings: CN¥0.055 loss per share (vs CN¥0.048 profit in 3Q 2023)

Shanghai Rightongene Biotechnology (SHSE:688217) Third Quarter 2024 Results

Key Financial Results

• Revenue: CN¥54.8m (down 23% from 3Q 2023).
• Net loss: CN¥3.49m (down by 235% from CN¥2.59m profit in 3Q 2023).
• CN¥0.055 loss per share (down from CN¥0.048 profit in 3Q 2023).

All figures shown in the chart above are for the trailing 12 month (TTM) period

Shanghai Rightongene Biotechnology Earnings Insights

Looking ahead, revenue is forecast to grow 24% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in China.

Performance of the Chinese Biotechs industry.

The company's shares are down 10% from a week ago.

Risk Analysis

We should say that we've discovered 1 warning sign for Shanghai Rightongene Biotechnology that you should be aware of before investing here.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.